Top

Gepubliceerd in:

01-06-2016

Het gebruik van MRI-scan bij prostaatkanker

Auteur: Dr. Stijn Heijmink

Gepubliceerd in: Bijblijven | Uitgave 4/2016

Samenvatting

Magnetische resonantie imaging (MRI) is een vorm van radiologische beeldvorming waarbij geen röntgenstraling maar radiofrequente golven gebruikt worden om wekedelenweefsels in het lichaam af te beelden. Het gebied van het kleine bekken, waarin zich ook de prostaat bevindt, is hiervoor uitstekend geschikt. Er wordt steeds vaker een MRI-scan verricht bij patiënten met (een verdenking op) prostaatkanker. Om inzicht te krijgen in de mogelijkheden van MRI bij prostaatkanker, is het van belang eerst enige informatie te verschaffen over de anatomie van de prostaat en de pathologie van prostaatkanker, alsook over de overige diagnostische hulpmiddelen en mogelijke therapiekeuzes.

vorige artikel Mammaradiologie – welke onderzoeken vraagt de huisarts aan?

volgende artikel Beeldvorming van de thorax bij rokers in de eerste lijn?

IKNL. Cijfers over kanker. http://www.cijfersoverkanker.nl/. Geraadpleegd op 29 maart 2016.

McNeal JE. Normal anatomy of the prostate and changes in benign prostatic hypertrophy and carcinoma. Semin Ultrasound CT MR. 1988;9(5):329–34.PubMed

Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer. 2000;89(8):1800–9.CrossRefPubMed

Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol. 1994;152(5 Pt 2):1709–13.PubMed

McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12(12):897–906.CrossRefPubMed

Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992;23(3):273–9.CrossRefPubMed

Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int. 2002;89(6):538–42.CrossRefPubMed

McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol. 1990;14(3):240–7.CrossRefPubMed

Ohori M, Scardino PT, Lapin SL, Seale-Hawkins C, Link J, Wheeler TM. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol. 1993;17(12):1252–61.CrossRefPubMed

10.

Saitoh H, Yoshida K, Uchijima Y, Kobayashi N, Suwata J, Kamata S. Two different lymph node metastatic patterns of a prostatic cancer. Cancer. 1990;65(8):1843–6.CrossRefPubMed

11.

Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–33.CrossRefPubMed

12.

Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm M‑O, et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. 2011;60(2):291–303.CrossRefPubMed

13.

Velonas VM, Woo HH, Remedios CG dos, Assinder SJ. Current status of biomarkers for prostate cancer. Int J Mol Sci. 2013;14(6):11034–60.CrossRefPubMedPubMedCentral

14.

Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 1980;40(12):4658–62.PubMed

15.

Ellis WJ, Brawer MK. The significance of isoechoic prostatic carcinoma. J Urol. 1994;152(6 Pt 2):2304–7.PubMed

16.

Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001;165(5):1554–9.CrossRefPubMed

17.

Scherr DS, Eastham J, Ohori M, Scardino PT. Prostate biopsy techniques and indications: when, where, and how? Semin Urol Oncol. 2002;20(1):18–31.CrossRefPubMed

18.

King CR, McNeal JE, Gill H, Presti JC. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys. 2004;59(2):386–91.CrossRefPubMed

19.

Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59(4):477–94.CrossRefPubMed

20.

Fütterer JJ, Heijmink SWTPJ, Scheenen TWJ, Jager GJ, Hulsbergen-Van de Kaa CA, Witjes JA, et al. Prostate cancer: local staging at 3‑T endorectal MR imaging – early experience. Radiology. 2006;238(1):184–91.CrossRefPubMed

21.

Heijmink SWTPJ, Fütterer JJ, Hambrock T, Takahashi S, Scheenen TWJ, Huisman HJ, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T – comparison of image quality, localization, and staging performance. Radiology. 2007;244(1):184–95.CrossRefPubMed

22.

Hövels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63(4):387–95.CrossRefPubMed

23.

Barrett T, Vargas HA, Akin O, Goldman DA, Hricak H. Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. Radiology. 2012;263(3):751–7.CrossRefPubMedPubMedCentral

24.

Vargas HA, Lawrence EM, Mazaheri Y, Sala E. Updates in advanced diffusion-weighted magnetic resonance imaging techniques in the evaluation of prostate cancer. World J Radiol. 2015;7(8):184–8.CrossRefPubMedPubMedCentral

25.

Hambrock T, Somford DM, Huisman HJ, Oort IM van, Witjes JA, Hulsbergen-van de Kaa CA, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259(2):453–61.CrossRefPubMed

26.

Hötker AM, Mazaheri Y, Aras Ö, Zheng J, Moskowitz CS, Gondo T, et al. Assessment of prostate cancer aggressiveness by use of the combination of quantitative DWI and dynamic contrast-enhanced MRI. AJR Am J Roentgenol. 2016;206(4):756–63.CrossRefPubMed

27.

Hoeks CMA, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SWTPJ, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261(1):46–66.CrossRefPubMed

28.

Vos EK, Kobus T, Litjens GJS, Hambrock T, Hulsbergen-van de Kaa CA, Barentsz JO, et al. Multiparametric magnetic resonance imaging for discriminating low-grade from high-grade prostate cancer. Invest Radiol. 2015;50(8):490–7.CrossRefPubMed

29.

Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68(6):1045–53.CrossRefPubMed

30.

Thompson JE, Leeuwen PJ van, Moses D, Shnier R, Brenner P, Delprado W, et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J Urol. 2016;195(5):1428–35.CrossRefPubMed

31.

Hoeks CMA, Hambrock T, Yakar D, Hulsbergen-van de Kaa CA, Feuth T, Witjes JA, et al. Transition zone prostate cancer: detection and localization with 3‑T multiparametric MR imaging. Radiology. 2013;266(1):207–17.CrossRefPubMed

32.

Steenbergen P, Haustermans K, Lerut E, Oyen R, De Wever L, Van den Bergh L, et al. Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation. Radiother Oncol. 2015;115(2):186–90.CrossRefPubMed

33.

Dinh CV, Steenbergen P, Ghobadi G, Heijmink SWTJP, Pos FJ, Haustermans K, et al. Magnetic resonance imaging for prostate cancer radiotherapy. Phys Med. 2016;32(3):446–51.CrossRefPubMed

34.

Scheenen TWJ, Heijmink SWTPJ, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, et al. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology. 2007;245(2):507–16.CrossRefPubMed

35.

Pondman KM, Fütterer JJ, Haken B ten, Schultze Kool LJ, Witjes JA, Hambrock T, et al. MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol. 2008;54(3):517–27.CrossRefPubMed

36.

ACR, PI-RADS v2. 2015 http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/PIRADS/PIRADS%20V2.pdf.

Titel: Het gebruik van MRI-scan bij prostaatkanker
Auteur: Dr. Stijn Heijmink
Publicatiedatum: 01-06-2016
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Bijblijven / Uitgave 4/2016
Print ISSN: 0168-9428
Elektronisch ISSN: 1876-4916
DOI: https://doi.org/10.1007/s12414-016-0136-3

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 4/2016

Redactioneel ten geleide

Een patiënt met een schildkliernodus of multinodulair struma; hoe nu verder?

Whole-body MRI: huidige stand van zaken en toekomstperspectief

Mammaradiologie – welke onderzoeken vraagt de huisarts aan?

Neuro-interventies in Nederland: de endovasculaire behandeling van neurovasculaire afwijkingen

Van X‑colon naar CT-colonografie, de historie en ontwikkelingen in de radiologie